The figures, for anyone assembling their own picture. Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about five days for tirzepatide, steady state at four to five half-lives, subcutaneous bioavailability high enough that site choice is irrelevant.

One thing that is still open after Dr.RenalNash’s answer:

Whether anyone has held 10mg long term rather than climbing, and what happened over the following year?

Dr.PeteFamMed said:

Numbers worth memorising for this class: Tmax one to three days for the weekly peptides, terminal half-life about a week for semaglutide and about…

Adding the part of the answer the thread has not reached. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

Reporting back.

Update: the eight-week restart pattern people described is exactly what happened. I nearly abandoned it at week five.

MASHdoc_SA said:

The pharmacokinetics explain nearly every practical question asked here.

Agreed on the mechanism, with the caveat that the head-to-head used semaglutide 1mg, not 2.4mg. It is still the best direct evidence available, but it is not the comparison most people think they are citing.

Correct me if the detail matters more than I have assumed.